Literature DB >> 22829164

Variation of the baseline characteristics and treatment parameters over time: an analysis of 15 years of growth hormone replacement in adults in the German KIMS database.

I Kreitschmann-Andermahr1, S Siegel, F Francis, M Buchfelder, H J Schneider, P H Kann, H Wallaschofski, M Koltowska-Häggström, G Brabant.   

Abstract

The purpose of this study is to examine potential implications of changes in the approach to adult growth hormone (GH) replacement (GHR) over the last 15 years. Therefore, we analysed the German KIMS database as one of the largest single country pharmacoepidemiological databases on adult GH deficiency (GHD). Based on the date of their first GH application patients were assigned to three intervals (1995-1999, 2000-2004, 2005-2009). A multivariate analysis of variance with interval and sex as independent variables was conducted. Differences were analysed with respect to IGF-I standard deviation score (SDS), quality of life, latency between GHD diagnosis and first GH dose, body mass index, waist-hip ratio, lipid profile, and GH dose. All analyses were conducted at baseline, 1 year, and 3 years of GHR. We detected significant associations between time interval and patient characteristics at baseline and with treatment effects. Recently, patients with less severe GHD (mean IGF-I SDS: -2.1, -1.6, -1.0 in the 1st, 2nd and 3rd interval; p = 0.000) are treated with lower GH starting doses (mean 0.30, 0.19, 0.21 mg/day in the 1st, 2nd and 3rd interval; p = 0.000). In the first time interval, IGF-I SDS was not normalized in females after 3 years of GHR. The results of our analysis demonstrate prominent changes in patient characteristics and handling of GHR. They highlight that approach to therapy and patient inclusion criteria change over time and may represent an important confounder for any analysis in epidemiological surveillance surveys.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22829164     DOI: 10.1007/s11102-012-0410-z

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  26 in total

1.  Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic Database.

Authors:  D Maiter; R Abs; G Johannsson; M Scanlon; P J Jönsson; P Wilton; M Koltowska-Häggström
Journal:  Eur J Endocrinol       Date:  2006-08       Impact factor: 6.664

2.  Sheehan's syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS - Pfizer International Metabolic Database.

Authors:  Fahrettin Kelestimur; Peter Jonsson; Senay Molvalilar; Jose Manuel Gomez; Christoph J Auernhammer; Ramiz Colak; Maria Koltowska-Häggström; Miklos I Goth
Journal:  Eur J Endocrinol       Date:  2005-04       Impact factor: 6.664

Review 3.  Regulating of growth hormone sensitivity by sex steroids: implications for therapy.

Authors:  Ken K Y Ho; James Gibney; Gudmundur Johannsson; Troels Wolthers
Journal:  Front Horm Res       Date:  2006       Impact factor: 2.606

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

5.  The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board.

Authors:  B A Bengtsson; R Abs; H Bennmarker; J P Monson; U Feldt-Rasmussen; E Hernberg-Stahl; B Westberg; P Wilton; C Wüster
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

6.  Growth hormone deficient patients after traumatic brain injury--baseline characteristics and benefits after growth hormone replacement--an analysis of the German KIMS database.

Authors:  I Kreitschmann-Andermahr; E M Poll; A Reineke; J M Gilsbach; G Brabant; M Buchfelder; W Fassbender; M Faust; P H Kann; H Wallaschofski
Journal:  Growth Horm IGF Res       Date:  2008-10-01       Impact factor: 2.372

7.  Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database).

Authors:  Lia P Gutiérrez; Maria Kołtowska-Häggström; Peter J Jönsson; Anders F Mattsson; Dag Svensson; Björn Westberg; Anton Luger
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-01       Impact factor: 2.890

8.  Cholesterol determination in high-density lipoproteins separated by three different methods.

Authors:  M F Lopes-Virella; P Stone; S Ellis; J A Colwell
Journal:  Clin Chem       Date:  1977-05       Impact factor: 8.327

9.  Gender of pediatric recombinant human growth hormone recipients in the United States and globally.

Authors:  Adda Grimberg; Elizabeth Stewart; Michael P Wajnrajch
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

Review 10.  [Gender-specific aspects in health care delivery and rehabilitation after an acute myocardial infarction].

Authors:  G Grande
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2008-01       Impact factor: 1.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.